"Octreotide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.
| Descriptor ID |
D015282
|
| MeSH Number(s) |
D04.345.566.650 D12.644.641.650
|
| Concept/Terms |
SMS 201-995- SMS 201-995
- SMS 201 995
- SMS 201995
- SM 201-995
- SM 201 995
- SM 201995
- Sandoz 201-995
- Sandoz 201 995
- Sandoz 201995
- Compound 201-995
- Compound 201 995
- Compound 201995
- SAN 201-995
- SAN 201 995
- SAN 201995
|
Below are MeSH descriptors whose meaning is more general than "Octreotide".
Below are MeSH descriptors whose meaning is more specific than "Octreotide".
This graph shows the total number of publications written about "Octreotide" by people in this website by year, and whether "Octreotide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 3 | 3 |
| 2009 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Octreotide" by people in Profiles.
-
Evaluation of coadministration schedules of rA1M for kidney protection after administration of 177Lu-octreotide. Radiat Prot Dosimetry. 2025 Aug 26; 201(13-14):995-1005.
-
Alpha-emitter therapy for pediatric relapsed metastatic pancreatic neuroendocrine tumor. Pediatr Blood Cancer. 2024 Jun; 71(6):e30961.
-
Co-administration with A1M does not influence apoptotic response of 177Lu-octreotate in GOT1 neuroendocrine tumors. Sci Rep. 2023 04 19; 13(1):6417.
-
Sirolimus efficacy in the treatment of critically ill infants with congenital primary chylous effusions. Pediatr Blood Cancer. 2022 02; 69(2):e29510.
-
Pediatric applications of Dotatate: early diagnostic and therapeutic experience. Pediatr Radiol. 2020 06; 50(7):882-897.
-
VISUAL VIGNETTE. Endocr Pract. 2017 Aug; 23(8):1031.
-
Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment. Clin Nucl Med. 2017 Jun; 42(6):436-443.
-
Octreotide long-acting repeatable among elderly patients with neuroendocrine tumors: a survival analysis of SEER-Medicare data. Cancer Epidemiol Biomarkers Prev. 2015 Nov; 24(11):1656-65.
-
Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014 May; 43(4):518-25.
-
Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis. Cancer. 2014 Jul 01; 120(13):2039-49.